Prestige Biopharma Limited
Clinical trials sponsored by Prestige Biopharma Limited, explained in plain language.
A biopharmaceutical company developing biosimilars and novel drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a copycat humira match the original? Results expected Jun 2027 (estimated)
-
Cheaper avastin copycat tested in healthy volunteers
Knowledge-focused CompletedThis study tested a new biosimilar drug called HD204 against the original Avastin in 119 healthy men. The goal was to see if the body processes both drugs the same way. Participants received a single dose, and researchers measured drug levels and safety. The trial is complete, bu…
Phase 1 • Sponsor: Prestige Biopharma Limited • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Biosimilar cancer drug put to the test in healthy volunteers
Knowledge-focused CompletedThis phase 1 trial tests whether a single dose of HD201, a biosimilar of the cancer drug trastuzumab (Herceptin), is processed by the body in the same way as the original European and US versions. Healthy male volunteers receive one intravenous infusion and have their blood level…
Phase 1 • Sponsor: Prestige Biopharma Limited • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC